Skip to content
DataLookout
Menu

NCT06772623

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

StatusRecruiting
PhasePhase 1/2
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 81 versions: 47 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 127 → 131 locations
  2. Minor Trial sites expanded: 124 → 127 locations
  3. Minor Study sites: 124 to 126
  4. Minor Study sites: 123 to 124
  5. Minor Study sites: 121 to 123
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 6 of 9 entries
    • Study sites revised (121)
  2. Minor Study sites: 119 to 121v75
  3. Minor Site details revised at 1 of 119 sitesv74
  4. Minor Study sites: 118 to 119v73
  5. Minor Study sites revised (118)v72
  6. Minor Study sites: 117 to 118v71
  7. Minor Study sites: 115 to 117v70
  8. Minor Study sites: 113 to 115v69
  9. Minor Study sites: 112 to 113v68
  10. Minor Study sites: 110 to 112v67
  1. Minor Trial sites expanded: 107 → 110 locationsv66
  2. Minor Study sites revised (107)v65
  3. Minor Study sites: 106 to 107v64
  4. Minor Study sites: 105 to 106v63
  5. Minor Study sites: 104 to 105v62
  6. Minor Study sites: 103 to 104v61
  7. Minor Study sites: 102 to 103v60
  8. Minor Study sites revised (102)v59
  9. Minor Trial sites expanded: 99 → 102 locationsv58
  10. Minor Study sites: 98 to 99v57
  11. Minor Study sites: 97 to 98v56
  12. Minor Trial sites expanded: 92 → 96 locationsv55
  13. Minor Study sites: 92 to 96v54
  14. Minor Trial sites expanded: 85 → 91 locationsv53
  15. Minor Site details revised at 1 of 91 sitesv52
  16. Minor Study sites: 85 to 91v51
  17. Minor Study sites: 83 to 85v50
  18. Minor Trial sites expanded: 64 → 79 locationsv49
  19. Minor Study sites: 79 to 81v48
  20. Minor Trial sites reduced: 74 → 64 locationsv47
  21. Minor Trial sites expanded: 55 → 74 locationsv46
  22. Minor Study sites: 55 to 74v45
  23. Minor Study sites: 53 to 55v44
  24. Minor Study sites: 52 to 53v42
  25. Minor Study sites: 50 to 52v41
  26. Minor Study sites revised (50)v40
  27. Minor Study sites: 49 to 50v39
  28. Minor Study sites: 48 to 49v38
  29. Notable Enrollment target: 132 to 252
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (9)
    • Site details revised at 1 of 48 sites
    v36
  30. Minor Enrollment target: 172 to 132v35 Show 4 more changesShow less
    • Study sites: 47 to 48
    • Secondary endpoints: 13 to 9
    • Study arms: 5 to 4
    • Study title shortened, about 1 word
  31. Minor Study sites: 46 to 47v34
  32. Minor Study sites: 43 to 46v33
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Timeframe: Up to Approximately 84 Days
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Timeframe: Up to Approximately 33 Months
Number of Participants with Adverse Events (AE)s
Timeframe: Up to Approximately 33 Months

Secondary (9)

Part 1 and Part 2: PFS as Assessed by Investigator
Part 1 and Part 2: DOR as Assessed by Investigator
Part 1 and Part 2: DC as Assessed by Investigator
Part 1 and Part 2: Overall Survival (OS)
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
Show 4 moreShow less
PD-L1 and c-Met Subgroups: PFS
PD-L1 and c-Met Subgroups: OS
PD-L1 and c-Met Subgroups: DOR
PD-L1 and c-Met Subgroups: DC

Arms and interventions

Part 1: Telisotuzumab Adizutecan + BudigalimabExperimental

Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration.

Part 2 Arm 1: Telisotuzumab Adizutecan + PembrolizumabExperimental

Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration.

Part 2 Arm 2: Telisotuzumab Adizutecan + PembrolizumabExperimental

Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration.

Part 2: Standard of CareExperimental

Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration.

Drugs: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin

Sites

131 sites in 17 countries

United States 27, China 15, Turkey (Türkiye) 11, Japan 10, Germany 9, Spain 8, Taiwan 8, France 7, Italy 7, Romania 6, Argentina 4, Australia 4, Belgium 4, Chile 4, Poland 4, United Kingdom 2, Puerto Rico 1